Abstract 5535
Background
PIK3CA mutations occur in ≈ 40% of HR+/HER2− breast cancers. In the phase III SOLAR-1 study (NCT02437318), ALP (PI3Kα inhibitor) + FUL significantly prolonged progression-free survival vs placebo (PBO) + FUL in patients (pts) with HR+/HER2− ABC, prior endocrine therapy, and PIK3CA mutations (HR 0.65; P < 0.001; Andre F, et al. NEJM. 2019). We report pt management details of key AESIs from SOLAR-1.
Methods
Pts received ALP + FUL (n = 284) or PBO + FUL (n = 287). Safety was assessed per CTCAE v4.03 and regardless of PIK3CA mutation status. We evaluated time to onset and management of key AESIs in patients receiving ALP.
Results
The median ALP treatment exposure was 5.5 mo. As previously reported, the most common any-grade AESIs were hyperglycemia, diarrhea, and rash (Table). Rates of ALP discontinuation and median times to onset and improvement are presented in the table. Supportive medication was frequently used to manage hyperglycemia, diarrhea, and rash. In pts with anti-rash medication initiated prior to onset of rash (n = 86), 60 (69.8%) received antihistamines. Use of anti-rash medication prior to onset of rash was associated with decreased frequency of rash (26.7% vs 53.9% in the overall population) and decreased reported grade (grade 3, 11.6% vs 20.1%). During the study, the implementation of more detailed AE management guidelines decreased treatment discontinuation due to any-grade AEs (29.2% vs 20.7%) and grade ≥ 3 events (18.1% vs 7.9%) between the first 50% of pts randomized and the last 50% of patients randomized.Table:
324P
Hyperglycemia | Diarrheaa | Rash | |
---|---|---|---|
n = 284 | |||
Pts with any-grade event, n (%) | 187 (65.8) | 164 (57.7) | 153 (53.9) |
-ALP discontinuation due to event, n (%) | 19 (10.2) | 8 (4.9) | 12 (7.8) |
-Received supportive medication, n (%) | 163 (87.2) | 104 (63.4) | 134 (87.6) |
-Most-common supportive medication for any-grade event, n (%) | Metformin, 142 (87.1) | Antipropulsives, 69 (66.3) | Steroids, 113 (84.3)b,c |
Pts with ≥ grade-3 event, n (%) | 110 (38.7)d | 19 (6.7) | 28 (9.9)e |
-Time to onset, median (range), days | 15 (5-395)d | 139 (10-470) | 13 (9-571)e |
-Time to improvement by ≥ 1 grade, median (95% CI), days | 6 (4-7)d,f | 18 (9-45) | 11 (8-NE)e |
Based on preferred term.
bNote that this is for pts who already had developed rash, which is different from pts who received medication before the onset of rash.
cIncludes both topical and systemic.
dBased on fasting plasma glucose values.
eBased on single preferred term.
fRange.
Conclusions
Adverse events associatated with ALP were manageable, improved with appropriate intervention (medication and/or ALP dose interruptions/modifications), and were generally reversible upon treatment discontinuation. Use of anti-rash medication prior to rash onset reduced the frequency and grade of rash.
Clinical trial identification
NCT02437318.
Editorial acknowledgement
Tara Wabbersen of MediTech Media, LLC funded by Novartis.
Legal entity responsible for the study
Novartis.
Funding
Novartis Pharmaceuticals Corp.
Disclosure
H.S. Rugo: Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer Inc.; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme Corp.; Research grant / Funding (institution): Novartis International AG; Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly and Company; Research grant / Funding (institution): Genentech, Inc.; Research grant / Funding (institution): Oklahoma Blood Institute; Research grant / Funding (institution): Odonate Therapeutics, Inc.; Research grant / Funding (institution): Daiichi Sankyo Company, Limited; Travel / Accommodation / Expenses: Mylan N.V.; Travel / Accommodation / Expenses: Amgen Inc.; Travel / Accommodation / Expenses: Puma Biotechnology, Inc. F. André: Research grant / Funding (institution): Novartis International AG; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer Inc.; Research grant / Funding (institution): Eli Lilly and Company; Research grant / Funding (institution): F. Hoffmann-La Roche Ltd. T. Yamashita: Honoraria (self), Research grant / Funding (institution): Chugai Pharma USA, Inc; Honoraria (self): Eisai Inc.; Honoraria (self): Novartis International AG; Honoraria (self): Taiho Oncology, Inc.; Honoraria (self), Research grant / Funding (institution): Nippon Kayaku Co.,Ltd.; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Kyowa Hakko Kirin Co., Ltd.; Honoraria (self): Pfizer Inc. J. Cruz Jurado: Honoraria (self): Novartis International AG; Honoraria (self): Genentech, Inc.; Honoraria (self): Elsai; Honoraria (self): Ipsen; Honoraria (self): EMD Serono. D. Juric: Honoraria (self): Novartis International AG; Honoraria (self): Genentech, Inc.; Honoraria (self): Eisai Inc.; Honoraria (self): Ipsen Pharma; Honoraria (self): EMD Serono, Inc. I. Mayer: Honoraria (self), Research grant / Funding (institution): Novarts International AG; Research grant / Funding (institution): Genentech, Inc.; Research grant / Funding (institution): Pfizer, Inc.; Honoraria (self): Eli Lilly and Company; Honoraria (self): AstraZeneca; Honoraria (self): GlaxoSmithKline plc.; Honoraria (self): MacroGenics, Inc. E.M. Ciruelos: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis International AG; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: F. Hoffmann-La Roche Ltd; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer Inc. H. Iwata: Honoraria (self), Research grant / Funding (institution): Novartis International AG; Honoraria (self): F. Hoffmann-La Roche via Chugai; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer, Inc.; Honoraria (self): Eli Lilly and Company; Honoraria (self): Daiichi Sankyo Company, Ltd. P.F. Conte: Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis International AG; Speaker Bureau / Expert testimony, Research grant / Funding (institution): F. Hoffmann-La Roche Ltd; Speaker Bureau / Expert testimony: Genentech, Inc.; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution): EMD Serono, Inc.; Travel / Accommodation / Expenses: Celgene Corporation. M. Campone: Research grant / Funding (institution): Novartis International AG; Honoraria (self), Research grant / Funding (institution): F. Hoffmann-La Roche Ltd; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer, Inc.; Honoraria (institution): Servier Laboratories; Honoraria (institution): Sanofy; Honoraria (institution): Accord; Research grant / Funding (institution): Tessaro. C. Wilke: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. D. Mills: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis International AG. M. Miller: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. S. Loibl: Honoraria (institution): Novartis International AG; Honoraria (institution): Pfizer, Inc.; Honoraria (institution): Celgene Corporation; Honoraria (institution): Amgen; Honoraria (institution): F. Hoffmann-La Roche Ltd; Honoraria (institution): AstraZeneca; Honoraria (institution): Abbvie; Honoraria (institution): Eli Lilly and Company; Honoraria (institution): Daiichi Sankyo Company, Ltd; Honoraria (institution): Eirgenix. All other authors have declared no conflicts of interest.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract